Stock events for RxSight, Inc. (RXST)
The past six months have seen significant volatility. In November 2025, RxSight reported a decrease in revenue compared to Q3 2024, primarily due to a decrease in Light Delivery Device (LDD) sales, but Light Adjustable Lens (LAL) procedure volume increased and the gross margin improved. In February 2026, the company reported an increase in LAL unit sales for the full year 2025, but total revenue decreased due to a decrease in LDD system sales compared to 2024. RxSight reported a wider net loss for 2025, but surpassed EPS and revenue forecasts for Q4 2025, with an improved gross margin. RxSight also issued its full-year 2026 revenue guidance, projecting lower year-over-year LDD placements. As of February 24, 2026, the share price had declined significantly from the previous year and underperformed the market.
Demand Seasonality affecting RxSight, Inc.’s stock price
RxSight's Light Adjustable Lens (LAL) sales can be influenced by typical seasonal trends, suggesting that demand for cataract surgery and related products may experience fluctuations throughout the year. Sequential LAL procedure growth reflected steady activity across the installed base, supported in part by recent commercial initiatives and typical seasonal trends. The revenue from capital equipment placement is sensitive to macroeconomic factors.
Overview of RxSight, Inc.’s business
RxSight, Inc. is a medical technology company focused on vision correction for cataract surgery patients through its Light Adjustable Lens (LAL) system. The company's core business revolves around its proprietary RxSight system, the first commercially available adjustable intraocular lens (IOL) technology, allowing ophthalmologists to customize a patient's vision after cataract surgery. The company sells capital equipment and generates recurring revenue from consumables.
RXST’s Geographic footprint
RxSight, Inc. has a commercial presence primarily in the United States. The company is also actively building international infrastructure and holds regulatory approvals for its RxSight system in North America, Europe, Singapore, South Korea, and Australia. As of Q3 2025, RxSight had an installed base of 1,109 Light Delivery Devices globally.
RXST Corporate Image Assessment
RxSight's focus on customized vision and its position as the sole provider of the FDA-approved post-operative adjustable Light Adjustable Lens (LAL) suggests a strong product-centric reputation within the ophthalmic medical device sector. The acceptance of RxSight's FDA Post-approval study results for publication reinforces its clinical credibility. The company's strategic initiatives indicate a proactive approach to maintaining and enhancing its standing with medical professionals.
Ownership
RxSight, Inc. has a mixed ownership structure, primarily held by institutional investors, insiders, and individual/retail investors. Institutional shareholders hold a significant portion of RxSight stock. Insiders, including executives and directors, collectively own shares in RxSight, Inc. The general public holds a stake in RxSight.
